Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 4,944,343 | -1,873,669 | -4,704,147 |
| Change in fair value of warrant liability | NaN | 0 | -858 |
| Change in fair value of investment option liability | NaN | 0 | 1,707 |
| Loss on write-off of deferred offering costs | 19,597 | NaN | NaN |
| Stock-based compensation | -498,416 | 186,981 | 400,108 |
| Amortization of intangibles | NaN | 0 | 42,180 |
| Depreciation expense | -81,953 | 40,369 | 78,824 |
| Other | NaN | -128,683 | NaN |
| Prepaid expenses and other current assets | 384,406 | -84,603 | -48,192 |
| Accounts payable, accrued expenses and other current liabilities | -121,408 | -284,682 | -11,300 |
| Due to related parties | 133,016 | -99,875 | -133,016 |
| Payment for offering costs previously accrued | NaN | NaN | 0 |
| Net cash used in operating activities | 4,099,841 | -2,074,956 | -4,281,724 |
| Proceeds from common stock sold for cash pursuant to the atm agreement, net of offering costs | NaN | 1,058,300 | 578,499 |
| Proceeds from the exercise of warrants, net of offering costs | NaN | 1,934,051 | 75,044 |
| Proceeds from sale of common stock and warrants, net of offering costs | -3,039,674 | 0 | 4,244,467 |
| Proceeds from the subscription receivable related to the issuance of inducement warrants and the exercise of warrants and preferred investment options | NaN | NaN | 0 |
| Proceeds from sale of common stock for cash pursuant to the atm agreement, net of offering costs | 1,298,415 | NaN | 0 |
| Net cash provided by financing activities | -5,387,153 | 2,992,351 | 4,898,010 |
| Effect of foreign exchange rate on changes on cash | 2,022 | -9,617 | -7,496 |
| Net increase in cash | -1,285,290 | 907,778 | 608,790 |
| Cash at beginning of period | 3,757,594 | 2,241,026 | NaN |
| Cash at end of period | 4,908,769 | 3,757,594 | NaN |